PRF Technologies Ltd Ordinary Shares PRFX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
PRF Technologies’ GridFeed(TM) to Explore Strategic Growth Opportunity in AI Data Center Power Optimization
-
PRF Technologies to Establish GridFeed™ as a Standalone Subsidiary to Pursue Strategic Alliances for Its AI-Driven Renewable Energy Trading Platform
-
PRF Technologies Provides First Half 2026 Business Update Highlighting Significant Progress Across Healthcare and AI Energy Business
-
PRF Technologies Issues Letter to Shareholders Highlighting Strengthened Financial Position and Building Momentum Across Its Biotechnology and AI-Driven Energy Platforms
Trading Information
- Previous Close Price
- $0.76
- Day Range
- $0.70–0.75
- 52-Week Range
- $0.69–7.95
- Bid/Ask
- $0.72 / $0.71
- Shares Outstanding
- 3.50M
- Market Cap
- $2.52M
- Volume/Avg
- 36,692 / 277,979
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 26.24
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
PRF Technologies Ltd is a a diversified platform spanning speciality pharmaceuticals, drug-delivery technologies, and AI-driven renewable-energy analytics. PRF Technologies focuses on pharmaceutical therapies that emphasize reformulation and sustained-release drug-delivery technologies and AI-driven energy analytics. PRF-110, the company's lead product, is based on the local anesthetic ropivacaine and targets the postoperative pain relief market. The company has two operating segments composed of the Clinical Development segment, which facilitates the development of potential new drug compounds, and the Solar segment, which comprises the design and development of the company's intellectual property and the sale related service offerings.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
- Website
- https://www.painreform.com
Valuation
|
Metric
|
PRFX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.15 |
Price/Sales | 26.24 |
Price/Cash Flow | — |
Price/Earnings
PRFX
Financial Strength
|
Metric
|
PRFX
|
|---|---|
Quick Ratio | 5.06 |
Current Ratio | 5.07 |
Interest Coverage | −22.49 |
Quick Ratio
PRFX
Profitability
|
Metric
|
PRFX
|
|---|---|
Return on Assets (Normalized) | −39.61% |
Return on Equity (Normalized) | −50.93% |
Return on Invested Capital (Normalized) | −47.13% |
Return on Assets
PRFX
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|t>H?%<!Y | LOCK|&&!<^ | $69B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|M#wB@gY$ | LOCK|H!z$ | $47B | |||
| Haleon PLC ADR
HLN
| LOCK|VQvcy> | LOCK|Ss! | $44B | |||
| Zoetis Inc Class A
ZTS
| LOCK|>Vh<!@n | LOCK|>C$ | $33B | |||
| Viatris Inc
VTRS
| LOCK|$?G@st& | LOCK|Rh | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|K% | LOCK|w# | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|?#$SMJ | LOCK|^> | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|^?R#Vn | LOCK|%Z@ | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|x?m#w>N | LOCK|#L@<& | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|m?WBV% | LOCK|&S | $2B |
United States